Navigation Links
Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
Date:9/24/2009

LAKE FOREST, Ill., Sept. 24 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of Fomepizole Injection, the generic equivalent of Antizol(R) from Paladin Labs, Inc.

(Logo:http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The addition of Fomepizole to Bioniche's product offering further broadens our base of niche injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Bioniche Pharma has the rights to market and distribute Fomepizole in the United States.

Bioniche will supply Fomepizole Injection in 1.5g /1.5 mL vials.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.

About Synerx Pharma:

Synerx Pharma, LLC is a privately held corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has six FDA approved products, of which four were First Time Generic Approvals, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at www.synerxpharma.com.

Antizol(R) is a registered trademark of Paladin Labs.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Reports Fiscal 2009 Year-End Results
2. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
3. Bioniche Repays Revolving Credit Facility
4. Bioniche Provides a Corporate Update
5. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
6. Bioniche Represented at House of Commons Sub-Committee on Food Safety
7. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
8. Bioniche Reports Fiscal 2009 Third Quarter
9. Bioniche Provides a Corporate Update
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Bioniche Revolving Credit Facility Maturity Date Amended
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... Dr. Jessica Barron, ... practice is now accepting new dental patients and families in the North Metro Denver ... care services from cleanings to cosmetic dentistry, and all in the most relaxing environment. ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former NFL ... a closer look at cases of TBI being managed by their members. The survey ... aging population, and identifies the challenges associated with their care. , During the week ...
(Date:2/10/2016)... St. Louis, Missouri (PRWEB) , ... February 10, ... ... 11-14, 2016, in San Diego, will bring together more than 200 of the ... in healthcare for the future. , “The true benefit of the Forum is ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit ... as the latest addition to its growing list of Partner Firms. S.S. ... Southeast, from Orlando to Huntsville and in between. , Harnessing the experience and ...
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016 Intouch ... recently identified an industry-wide trend regarding the evolution ... allows organizations to efficiently deliver compelling sales presentations ... 2011 and another in 2015, Intouch uncovered that ... tablet devices and DSAs, many are not using ...
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... , Feb. 9, 2016  Until recently, the ... surgery or liposuction. Thankfully, the FDA approved the non-invasive ... to death. Coolsculpting was originally approved in 2010 for ... thighs and now the chin. With this add-on approval, ... can use a smaller applicator, the CoolMini, to address ...
Breaking Medicine Technology: